SRRK earnings analysis
What we found in SRRK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Scholar Rock reported Q1 2026 results, with no revenue generated, and a diluted EPS of -$0.83, falling short of estimates. Net loss deepened to $105.5 million from $74.7 million in Q1 2025, highlighting ongoing financial struggles ahead of a crucial product launch decision by the FDA due by September 30, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue Recorded
- Scholar Rock reported zero revenue for Q1 2026, consistent with the entire previous fiscal year.
- Increased Net Loss
- Net loss rose to $105.5 million for Q1 2026, compared to $74.7 million in Q1 2025, reflecting a 41.2% increase.
- Higher Operating Expenses
- Total operating expenses surged by 32.3% to $102.0 million, driven by higher R&D and G&A costs.
- Increased Cash & Equivalents
- Cash and cash equivalents improved to $430.5 million from $323.5 million in December 2025.
- Significant Debt Financing
- Secured $350 million total in new debt financing in February 2026, providing a potential safety net.
- FDA BLA Submission Accepted
- Resubmitted BLA for apitegromab was accepted by the FDA with a PDUFA action date set for September 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Revenue History
- The company has not generated any revenue to date, raising concerns about financial sustainability.
- Increasing Operating Losses
- Operating losses increased significantly, indicating ongoing challenges in shifting towards profitability.
- Regulatory Risks
- The FDA's prior rejection adds pressure, and there could be significant delays to commercialization if problems persist.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.83
What they said about what is next.
Management indicated continued operating losses expected and emphasized the importance of future FDA decisions.
The filing reads worse than the one before it.
What came before.
- 10-K · March 3, 2026
- The 2025 10-K positions Scholar Rock as a pipeline-focused biotech transitioning toward commercialization, centered on apitegromab (SMA) with regulatory milestones including a BLA submitted in January 2025 and EMA MAA…
- 10-Q · November 14, 2025
- Scholar Rock reported a Q3 2025 net loss of $102,220 (three months ended September 30, 2025) or $(0.90) per share, versus a net loss of $64,479 or $(0.66) per share in Q3 2024, driven by a sharp rise in operating…
- 10-Q · August 6, 2025
- Scholar Rock reported a wider loss in Q2 2025 as operating expenses rose sharply; net loss was $110.0M (-$0.98 per share) vs $58.5M (-$0.60) in Q2 2024. Management highlights regulatory progress for apitegromab (BLA…
- 10-K · February 27, 2025
- Scholar Rock reported a positive pivotal Phase 3 (SAPPHIRE) top-line in October 2024 and submitted a U.S. BLA in January 2025 with an EU filing planned in Q1 2025; management expects to initiate a U.S. commercial launch…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SRRK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever